Implications of high hemoglobin, elevated packed cell volume, increased red blood cell count, normal white blood cell count, oxygen saturation of 98%, and erythropoietin level within reference range:
The presence of elevated hemoglobin, hematocrit (packed cell volume), and red blood cell (RBC) count alongside a normal white blood cell count and normal oxygen saturation (98%) suggests a state of erythrocytosis with adequate oxygenation but without inflammatory or leukocytic response. An erythropoietin (EPO) level of 7 mIU/mL, which lies within the normal reference range (4 to 29 mIU/mL), generally indicates that the erythrocytosis is unlikely to be due to secondary causes driven by hypoxia-induced elevated erythropoietin production, such as chronic lung disease or high altitude hypoxia NICE CKS.
Given normal oxygen saturation, secondary erythrocytosis from hypoxic causes is improbable, and the normal EPO level further argues against inappropriate or excessive erythropoietin secretion, such as from renal tumors or other EPO-producing neoplasms NICE CKS. Additionally, the normal white blood cell count implies absence of polycythemia vera-associated leukocytosis, and hence a primary myeloproliferative neoplasm is less likely but not entirely excluded without further testing such as JAK2 mutation analysis NICE CKS.
The combination of elevated red cell mass with normal EPO and normal oxygen saturation may suggest idiopathic erythrocytosis or a rare inherited high-oxygen-affinity hemoglobin variant, conditions which cause tissue hypoxia at the cellular level by abnormal hemoglobin oxygen unloading despite normal arterial oxygen saturation NICE CKS Repp & McMahon B 2026. These rare Hb variants increase hemoglobin oxygen affinity and thus impair oxygen delivery to tissues, stimulating increased RBC production despite normal systemic oxygenation levels Repp & McMahon B 2026. Detection of these variants typically requires specialized genetic testing of globin genes NICE CKS Repp & McMahon B 2026.
In the absence of elevated EPO and hypoxia, and with no leukocytosis or thrombocytosis, apparent erythrocytosis due to reduced plasma volume should also be considered, especially in contexts with risk factors like dehydration, diuretics, smoking, or alcohol excess NICE CKS. However, elevated RBC mass (true erythrocytosis) is defined by hematocrit levels exceeding 0.60 in men and 0.56 in women and needs confirmation by red cell mass measurement or repeat testing NICE CKS.
From a clinical risk perspective, elevated hemoglobin and hematocrit cause increased blood viscosity, raising the thrombotic risk regardless of underlying cause, mandating cardiovascular risk factor management and monitoring NICE CKS,NICE CKS. Phlebotomy may be considered when symptoms of hyperviscosity arise, but in cases such as high-affinity hemoglobin variants, routine phlebotomy is not always recommended unless symptoms occur, as data on benefit is limited NICE CKS Repp & McMahon B 2026. Regular monitoring and careful assessment for thrombotic events and progression are advised NICE CKS,NICE CKS.
In summary, elevated hemoglobin, hematocrit, and RBC count with normal white cells, normal oxygen saturation, and a normal erythropoietin level indicate erythrocytosis not driven by hypoxia or secondary erythropoietin overproduction, pointing towards idiopathic erythrocytosis or rare hemoglobinopathies such as high-oxygen-affinity hemoglobin variants. These require further evaluation including molecular testing to exclude polycythemia vera and other myeloproliferative disorders as well as genetic hemoglobinopathy screening, with management focused on monitoring and cardiovascular risk control NICE CKS,NICE CKS Repp & McMahon B 2026.
Key References
- NICE CKS: Polycythaemia/erythrocytosis
- NICE CKS: Erythrocytosis/polycythaemia
- SmPC: Retacrit 8 000 IU/0.8 mL solution for injection in pre-filled syringe
- SmPC: Retacrit 6 000 IU/0.6 mL solution for injection in pre-filled syringe
- SmPC: Retacrit 40 000 IU/1 mL solution for injection in pre-filled syringe
- SmPC: Retacrit 3 000 IU/0.9 mL solution for injection in pre-filled syringe
- (Repp and McMahon B., 2026): Hemoglobin San Diego: A Case Report and Review of the Literature.
- (Abdullahi et al., 2025): Erythropoietic indices in asthma patients on controller medications: a comparative analysis.
- (Livshits et al., 2026): Comparison of Red Blood Cell Features in Israeli Circassians: The Possible Effect of Residential Altitude.